Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
narlumosbartmab + doxorubicin + cisplatin + methotrexate + ifosfamide
- Development stage
- Unknown
- Lead developer
- Peking University People's Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous, Intravenous
01
Overview
This combination therapy consists of narlumosbartmab, a humanized monoclonal antibody targeting the Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL), and a standard neoadjuvant chemotherapy regimen known as the PKUPH-OS protocol (comprising doxorubicin, cisplatin, methotrexate, and ifosfamide). Developed and investigated by Peking University People's Hospital, this regimen is specifically designed for the treatment of bone-derived malignancies characterized by osteolytic lesions and multinucleated giant cells. Narlumosbartmab works by inhibiting osteoclast activity, which is intended to clarify tumor boundaries and reduce surgical difficulty, while the chemotherapy components provide systemic cytotoxic effects by inducing DNA damage and inhibiting metabolic pathways essential for tumor cell proliferation.
- Brand names
- Mailishu
- Other names
- narlumosbart + doxorubicin + cisplatin + methotrexate + ifosfamidenarlumosbart + PKUPH-OS regimen
02
Targets
DHFR (Dihydrofolate reductase)DNARANKL (Receptor Activator for Nuclear Factor-kappa B Ligand)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on narlumosbartmab + doxorubicin + cisplatin + methotrexate + ifosfamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on narlumosbartmab + doxorubicin + cisplatin + methotrexate + ifosfamide.